Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas.
Stefan KüfferJessica GrabowskiSatoru OkadaNikolai SojkaStefan WelterAlexander von Hammerstein-EquordMarc HinterthanerLucia CordesXenia von HahnDenise MüllerChristian SauerHanibal BohnenbergerAlexander MarxPhilipp StroebelPublished in: Cancers (2022)
Using indirect and direct phosphoproteomic analyses to predict sunitinib response in malignant TET, we have shown that TH and TC express multiple important sunitinib target RTKs. Among these, TYRO3 was identified as a potent mediator of sunitinib resistance activity, specifically in metastatic TH. TYRO3 may thus be both a novel biomarker of sunitinib resistance and a potential therapeutic target in advanced thymomas and thymic carcinomas.